Oncology Biotech Revolution Medicines Files for IPO

Revolution Medicines, an Illinois Ventures portfolio company, filed documents with the SEC regarding an initial public offering. The Company applied for a Nasdaq listing under the stock symbol RVMD. This news follows a recent presentation on the company’s SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference and a $100M Series C raise announced in July 2019.

Revolution Medicines is a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive high-value frontier cancer targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

To read the more, click here. To learn more about Revolution Medicines, click here.